Patent Application
20240335678
The present disclosure relates to a conversion device for converting a treatment beam for treating a subject's lesion.
Charged particle beams such as proton beams are used to treat lesions such as brain tumors.
During treatment, a large amount of radiation may be radiated to a patient's normal tissues in a proton beam's path so that the normal tissues are also affected by the radiation. For example, in the process of treating a patient's brain tumor with a proton beam, hair loss may be caused by the proton beam.
In particular, hair loss can have a very negative impact on the school and the social life of pediatric and female patients suffering from brain tumors, significantly reducing the quality of life of the patients.
The present disclosure is aimed at providing a conversion device for converting a treatment beam that allows normal tissues in the path of beams to be less affected by the beams during treatment using a charged particle beam such as a proton beam.
The present disclosure may provide a conversion device for converting a treatment beam to treat a subject's lesion, including a collimator unit on which the treatment beam is incident and where a plurality of slits are formed; and a scattering unit that scatters the treatment beam that has passed through the collimator unit.
The treatment beam may include a charged particle bean.
The charged particle beam may include any one of a proton beam, a helium ion beam, and a carbon ion beam.
Each of the plurality of slits may extend long, the plurality of slits may be formed side by side, and the treatment beam may be spatially divided by the slit.
The treatment beam may be incident on the plurality of slits at different angles, and the direction in which one of the plurality of slits extends may be parallel to a corresponding incidence angle.
The distance in which the shortest one of the plurality of slits extends in the direction in which the treatment beam moves may be 1.5 to 10 times the longest depth to which the treatment beam penetrates.
The collimator unit may include first and second collimator units arranged in the direction in which the treatment beam moves.
The collimator unit may be made of either brass or tungsten.
The collimator unit may be concave toward the lesion.
The plurality of scattering units may have their respective levels of scattering, and it may be possible for a user to select any one of them.
The scattering unit may include a first scattering unit and a second scattering unit located between the first scattering unit and the lesion, and the first scattering unit and the second scattering unit may respectively include a plurality of scattering units having their respective levels of scattering.
The treatment beam that has passed through the scattering unit may irradiate the lesion, and the treatment beam may turn into an undivided beam in the lesion.
The scattering unit may include a metal plate.
The metal of the metal plate may have a density of 10 g/cm3 to 25 g/cm3.
The metal of the metal plate may include any one of lead, bismuth, and tungsten.
The treatment beam may be converted into spatially divided radiation for treatment while passing through the collimator and the scattering unit, and the conversion device may further include an absorption unit located between the scattering unit and the lesion and absorbing at least some of the radiation.
The absorption unit may be made of either a polymer with a density of 0.7 g/cm3 to 2 g/cm3 or a metal with a density of 2 g/cm3 to 6 g/cm3.
The total thickness of the air layer between the collimator unit and the absorption unit may be adjustable and may range from 1 cm to 8 cm.
The distance between the absorption unit and the lesion may be adjustable.
The conversion device may further include a range shifter that is located between a treatment beam delivery device for delivering the treatment beam and the collimator unit, allows the depth to which the treatment beam penetrates in the subject to become shallower, and is detachable.
The present disclosure provides a conversion device for converting a treatment beam to treat a subject's lesion, including a collimator unit that increases a PVDR of an incident treatment beam and allows the treatment beam remaining undivided to turn spatially divided; and a scattering unit that scatters the treatment beam that has passed through the collimator unit.
A plurality of slits may be formed in the collimator unit, and the PVDR of the treatment beam that has passed through the collimator unit may monotonically decrease depending on the depth to which the treatment beam penetrates.
The treatment beam that has passed through the scattering unit may be radiated to the lesion with the PVDR reduced to 1.0 to 1.2.
The present disclosure provides a conversion device for converting a treatment beam that allows normal tissues to be less affected by beams during treatment using a charged particle beam such as a proton beam.
Hereinafter, the present disclosure will be described in more detail with reference to the drawings.
The attached drawings are provided merely as examples to describe the technology of the present disclosure in more detail, and the technology of the present disclosure is not limited to the drawings. For explanation purposes, the thickness or the length of each part may be exaggerated in the appended drawings.
In the following embodiments of the present disclosure, the description is made by taking a proton beam as an example of treatment beams, but the treatment beam according to the present disclosure may be one of charged particle beams. The charged particle beam may be any one of a proton beam, a helium ion beam, and a carbon ion beam.
In addition, in the following embodiments, the description is made by taking a tumor in the brain as an example of lesions to be treated, but the position and the type of a lesion to be treated according to the present disclosure are not limited thereto.
The conversion device 1 may be used by being connected to the end of a proton beam delivery device for delivering a generated proton beam to a patient.
The proton beam delivery device may rotate by being connected to a gantry. A patient (subject) lies on a bed located at an extension of the proton beam delivery device, and a proton beam is radiated to the patient's lesion after passing through the conversion device.
The specific shape of the proton beam delivery device may change depending on the location of a lesion, etc., and a patient's posture may also change during treatment.
As shown in
In addition,
The range shifter 10, the collimator unit 20, the scattering unit 30, and the absorption unit 40 may be sequentially arranged between the proton beam delivery device and a lesion, and a proton beam may be radiated to the lesion by sequentially passing through the range shifter 10, the collimator unit 20, the scattering unit 30, and the absorption unit 40.
A proton beam that has passed through the conversion device 1 may be radiated to a tumor, which is a lesion to be treated, by passing through a patient's scalp, skull, and normal brain.
A proton beam radiated to the scalp, which has to be protected from the proton beam, may be spatially divided, and the peak-valley dose ratio (PVDR) thereof may be high. The PVDR may be calculated by dividing Dp (dose at peak) by Dv (dose at valley).
In the present disclosure, “spatial division” means forming a spatially periodic dose distribution. The spatial division may be regarded as a state where the PVDR of a proton beam is greater than 1.1, greater than 1.2, or greater than 1.5, and actually 1.1 to 200, 1.2 to 200, or 1.5 to 200.
The PVDR of a proton beam incident on the scalp may be 3.0 to 100.
As a spatially divided proton beam passes through the scalp, the skull, and the normal brain, a low-dose area may be formed along the beam's path, so that normal tissue may be protected and, in particular, hair loss may be reduced.
Afterwards, after the proton beam has reached a lesion to be treated, the spatial division of the beam may be converted to undivided state, the low-dose area may disappear, and the PVDR may approach 1. The lesion may be treated effectively as the dose becomes constant. The PVDR of the proton beam radiated to the lesion may be 1.0 to 1.1 or 1.0 to 1.2.
As described above, according to the present disclosure, a state of high spatial division may be maintained in normal tissues, and a state of undivided may be maintained in tumors. As a result, normal tissues may be protected as much as possible, and tumors may be treated effectively.
Hereinafter, the conversion device according to the present disclosure will be described in detail with reference to
The range shifter 10 is placed between the proton beam delivery device and the collimator unit 20. The range shifter 10 may change the depth to which a proton beam penetrates in a subject, and, in particular, as shown in
The collimator unit 20 may have a plurality of slits 21 formed therein. Each of the plurality of slits 21 may extend long and may be arranged side by side with each other.
The collimator unit 20 may spatially divide an incident proton beam and cause a PVDR to monotonically decrease based on the traveling distance in a subject.
The collimator unit 20 may be made of brass or tungsten.
As shown in
As in the present disclosure, when an incidence angle and a slit's extension direction are parallel to each other (defocusing slit), the outline of the dose on the skin may be flat, and the dose distribution may be uniform even in lesions. In contrast, when an incidence angle and a slit extension direction do not match and slits are parallel to each other (parallel slit), the outline of the dose on the skin may not be flat but curved. In this case, the dose distribution may not be uniform even in lesions.
The distance d1 in which the shortest slit 21 extends, that is, the thickness of the collimator unit 20, may be 1.5 to 10 times the longest depth to which a proton beam penetrates. When the distance d1 is less than or equal to 1.5 times the longest depth to which a proton beam penetrates, it may be difficult to monotonically decrease a PVDR. When the distance d1 is equal to or more than 10 times the longest depth to which a proton beam penetrates, too much of the proton beam may be lost, so that treatment takes a very long time. In addition, in that case, a collimator may be difficult to handle.
According to another embodiment of the present disclosure, the width d2 of the slit 21 may increase toward the outside of a collimator.
As shown in
The scattering unit 30 may be made of a metal plate or may be made of a plurality of metal plates having different thicknesses.
Each scattering unit 30 may be mounted on the selection unit 50. The selection unit 50 may include a through hole 51, and a proton beam that has been spatially divided while passing through the collimator unit 20 may be incident on the through hole 51. It may be possible for a user to place the scattering unit 30 with a desired scattering level among a plurality of scattering units 30 in the through hole 51.
The scattering level of the scattering unit 30 may be adjusted by adjusting the material and/or the thickness of a metal plate. The metal plate may be made of a metal with a density of 10 to 25, and may be specifically made of any one of lead, bismuth, and tungsten.
The scattering unit 30 may allow a proton beam to be in a state of undivided based on the depth of a tumor. That is, the scattering unit 30 may determine a depth at which a PVDR of a spatially divided proton beam becomes lower than 1.2 or 1.1.
In the computer simulation, the energy of the proton beam was 161 MeV, the width of the collimator made of brass was 2.5 mm, the width of the slits was 2.5 mm, the distance between the slits was 5 mm, and the extension length of the slits was 10 cm. It is assumed that the medium was filled with water.
The absorption unit 40 may be placed between the scattering unit 30 and a lesion and remove radiation generated or scattered by the range shifter 10, the collimator unit 20, the scattering unit 30, etc.
The absorption unit 40 may be made of either a polymer with a density of 0.7 g/cm3 to 2 g/cm3 or a metal with a density of 2 g/cm3 to 6 g/cm3. The metal used for the absorption unit 40 may be aluminum or titanium.
The sum of the thicknesses of the air layers between the collimator unit 20 and the absorption unit 40 may be adjustable and may be 1 cm to 8 cm. As shown in
The uniformity of dose in a tumor may be controlled by controlling the sum of the thicknesses of the air layers. When the sum of the thicknesses of the air layers is increased, the uniformity of dose in the tumor may be improved. However, a PVDR of a proton beam radiated to the scalp may decrease.
It may be possible to adjust the distance between the conversion device 1 described above and a lesion.
Hereinafter, it will be described how to treat a patient using the conversion device according to the first embodiment of the present disclosure.
First, a treatment plan may be established by determining the position, the condition, etc. of a patient's lesion.
The treatment plan may include information on the maximum energy of a proton beam, the location of irradiation, treatment time, the selection of the conversion device 1, the location where the conversion device 1 will be placed, etc.
The components of the conversion device 1 may be selected for a proton beam to remain divided and turn undivided when reaching a lesion. The selection of the scattering unit 30 may be the most important, and, when selecting the scattering unit 30, whether to use the range shifter 10, the distance between the absorption unit 40 and a lesion, etc. may be taken into consideration.
After the conversion device 1 designed as desired is coupled with a device for generating a proton beam and a patient is placed, the proton beam may be radiated.
As the proton beam passes through the range shifter 10, the depth to which the proton beam penetrates in a patient's body may become shallower. Afterwards, as the proton beam may be spatially divided while passing through the collimator unit 20, the PVDR may decrease monotonically. As the proton beam is scattered while passing through the scattering unit 30, the depth at which the proton beam turns undivided may be determined. Afterwards, after scattered radiation is removed while the proton beam passes through the absorption unit 40, the proton beam may be incident on the patient.
A proton beam may remain divided and have a high PVDR of 1.2 or more in a patient's normal tissues, but may turn undivided and have a PVDR of 1.2 or less when reaching a lesion. As a result, it may be possible to reduce the influence of a proton beam on normal tissues and effectively treat lesions with the proton beam.
Hereinafter, the second to fourth embodiments of the present disclosure will be described with reference to
As shown in
Referring to
Referring to
For example, when the first scattering unit 30a has metal plates with a thickness of 10 mm, 20 mm, and 30 mm, respectively, and the second scattering unit 30b has metal plates with a thickness of 3 mm, 5 mm, and 7 mm, respectively, it may be possible for a user to use metal plates with a thickness of 10 mm, 13 mm, 15 mm, 17 mm, 20 mm, etc., respectively, by combining the two scattering units.
The first scattering unit 30a and the second scattering unit 30b may be spaced apart from each other, and, in this case, the total thickness of the air layer according to the fourth embodiment may include the distance between the first scattering unit. 30a and the second scattering unit 30b.
The above-described embodiments are examples for describing the present disclosure, and the present disclosure is not limited thereto. A person having ordinary skill in the technical field to which the present disclosure belongs would be able to carry out the present disclosure by making various modifications to the above-described embodiments, so the scope of the technology of the present disclosure should be determined by the appended claims.
| Number | Date | Country | Kind |
|---|---|---|---|
| 10-2021-0096045 | Jul 2021 | KR | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/KR2022/008935 | 6/23/2022 | WO |
